All In Biotech

Drug Trial Radar · NCT00561470

Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxaliplatin Based Regimen

Last checked: Nov 20, 2026Latest source record: Sep 28, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,226 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,226

Actual

Start

Nov 2007

Primary completion

Feb 2011

Study completion Jun 2012

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals; NSABP Foundation Inc
First posted
Nov 21, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the study was to evaluate the effectiveness of aflibercept (versus placebo) in increasing the overall survival in participants with metastatic colorectal cancer treated with FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) and that have previously failed an oxaliplatin based treatment for metastatic disease. The secondary objectives were to compare progression-free survival, to evaluate overall response rate, to evaluate the safety profile, to assess immunogenicity of intravenous (IV) aflibercept, and to assess pharmacokinetics of IV aflibercept in both treatment arms.

Conditions

  • Colorectal Neoplasms
  • Neoplasm Metastasis

Interventions

  • PlaceboDrug

    4 mg/kg of sterile aqueous buffered vehicle (pH 6.0) was administered intra venously (IV) over 1 hour on Day 1, every 2 weeks

  • Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)Drug

    4 mg/kg of Aflibercept was administered IV over 1 hour on Day 1, every 2 weeks.

  • FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)Drug

    The FOLFIRI regimen was initiated immediately after Placebo administration on Day 1 The FOLFIRI regimen included: * 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by: * 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by: * 5-FU 2400 mg/m² continuous IV infusion over 46-hours

  • FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)Drug

    The FOLFIRI regimen was initiated immediately after Aflibercept administration on Day 1 The FOLFIRI regimen included: * 180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by: * 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by: * 5-FU 2400 mg/m² continuous IV infusion over 46-hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years)

Locations

221 sites in 28 countries. Site status is shown where the registry gives one.

  • Sanofi-Aventis Investigational Site Number 840119

    Birmingham, Alabama

  • Sanofi-Aventis Investigational Site Number 840074

    Muscle Shoals, Alabama

  • Sanofi-Aventis Investigational Site Number 840093

    Hot Springs, Arizona

  • Sanofi-Aventis Investigational Site Number 840080

    Anaheim, California

  • Sanofi-Aventis Investigational Site Number 840076

    Fountain Valley, California

  • Sanofi-Aventis Investigational Site Number 840120

    Fountain Valley, California

  • Sanofi-Aventis Investigational Site Number 840073

    Greenbrae, California

  • Sanofi-Aventis Investigational Site Number 840101

    Hayward, California

  • Sanofi-Aventis Investigational Site Number 840046

    La Jolla, California

  • Sanofi-Aventis Investigational Site Number 840116

    Loma Linda, California

  • Sanofi-Aventis Investigational Site Number 840048

    Long Beach, California

  • Sanofi-Aventis Investigational Site Number 840201

    Oakland, California

  • Sanofi-Aventis Investigational Site Number 840901

    Roseville, California

  • Sanofi-Aventis Investigational Site Number 840042

    Sacramento, California

  • Sanofi-Aventis Investigational Site Number 840301

    Sacramento, California

  • Sanofi-Aventis Investigational Site Number 840112

    Salinas, California

  • Sanofi-Aventis Investigational Site Number 840006

    San Diego, California

  • Sanofi-Aventis Investigational Site Number 840106

    San Diego, California

  • Sanofi-Aventis Investigational Site Number 840206

    San Diego, California

  • Sanofi-Aventis Investigational Site Number 840306

    San Diego, California

  • Sanofi-Aventis Investigational Site Number 840406

    San Diego, California

  • Sanofi-Aventis Investigational Site Number 840506

    San Diego, California

  • Sanofi-Aventis Investigational Site Number 840606

    San Diego, California

  • Sanofi-Aventis Investigational Site Number 840706

    San Diego, California

  • Sanofi-Aventis Investigational Site Number 840806

    San Diego, California

  • Sanofi-Aventis Investigational Site Number 840906

    San Diego, California

  • Sanofi-Aventis Investigational Site Number 840401

    San Francisco, California

  • Sanofi-Aventis Investigational Site Number 840601

    San Jose, California

  • Sanofi-Aventis Investigational Site Number 840501

    Santa Clara, California

  • Sanofi-Aventis Investigational Site Number 840801

    South San Francisco, California

  • Sanofi-Aventis Investigational Site Number 840001

    Vallejo, California

  • Sanofi-Aventis Investigational Site Number 840701

    Walnut Creek, California

  • Sanofi-Aventis Investigational Site Number 840071

    Stamford, Connecticut

  • Sanofi-Aventis Investigational Site Number 840014

    Newark, Delaware

  • Sanofi-Aventis Investigational Site Number 840089

    Boynton Beach, Florida

  • Sanofi-Aventis Investigational Site Number 840041

    Gainesville, Florida

  • Sanofi-Aventis Investigational Site Number 840031

    Gainesville, Florida

  • Sanofi-Aventis Investigational Site Number 840122

    Miami, Florida

  • Sanofi-Aventis Investigational Site Number 840079

    The Villages, Florida

  • Sanofi-Aventis Investigational Site Number 840087

    Chicago, Illinois

Showing 40 of 221 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.